Pancreatic acinar metaplasia at the gastroesophageal junction is associated with protective effect against intestinal metaplasia in patients with gastroesophageal reflux disease

Anecdotal evidence suggests that pancreatic acinar metaplasia (PAM) and intestinal metaplasia (IM) overlap infrequently at the gastroesophageal junction/distal esophagus (GEJ/DE). The goal of this study was to evaluate the significance of PAM at GEJ/DE in relation to IM in patients with gastroesophageal reflux disease (GERD). Group 1 comprised 230 consecutive patients with GEJ/DE biopsies (80.6% with GERD symptoms). Group 2 comprised 151 patients with established GERD and GEJ/DE biopsies taken before Nissen fundoplication. Group 3 comprised 540 consecutive patients used for a follow-up study of PAM. PAM was present in 15.7%–15.9% and IM in 24.8%–31.1% of patients in groups 1 and 2, respectively. PAM-IM overlap was present in 2.2%–3.3%, respectively. Patients with PAM were, on average, 6–12 years younger than patients with IM, and were predominantly female (72.2%–75%), in contrast to patients with IM (47.3%–32%). In the unadjusted logistic regression model, patients with PAM were 69%–65% less likely to also have IM, as compared to patients without PAM. In the fully adjusted model, patients with PAM were 35%–61% less likely to also have IM, although the P-value was not significant. Follow-up analysis of patients with PAM from group 3 (n = 28) demonstrated the prevalence of IM and PAM in subsequent biopsies at 7.1% and 60.7%, respectively. No cases showed PAM-IM overlap on follow-up. The data suggests that PAM at the GEJ/DE is associated with protective effect against IM and thus could be useful as a marker of decreased susceptibility to IM. •Pancreatic metaplasia at the gastroesophageal junction is common in reflux disease.•It is seen in predominantly p][younger females in contrast to intestinal metaplasia.•It is associated with protective effect against Intestinal metaplasia.